Latham & Watkins advised GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, in a strategic collaboration with Samsung C&T (SCT) and Samsung Electronics (SEC) to bring GRAIL’s GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. In connection with the strategic collaboration, SCT and SEC agreed to invest US$110 million into GRAIL at a price of US$70.05 per share of common stock. The firm also advised GRAIL in its US$325 million private placement financing pursuant to a securities purchase agreement with new and existing institutional investors.
The Latham & Watkins LLP team who advised GRAIL on these transactions was led by Los Angeles partner Alex Voxman and Orange County/ Bay Area partner Ross McAloon, with associates Raul Gonzalez-Casarrubias and Edwin Gonzalez. Advice was also provided on collaboration, and intellectual property matters by San Diego partner Steve Chinowsky and counsel Robert Yeh; on US regulatory matters by Washington, D.C. partner James Barker and counsel Catherine Hein; on FDA regulatory matters by Washington, D.C. partner Liz Richards; and on tax matters by Los Angeles partner Pardis Zomorodi, Houston partner Jared Grimley and counsel William Kessler.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.